Skip to main content

Teflaro Side Effects

Generic name: ceftaroline

Medically reviewed by Last updated on Apr 1, 2024.

Note: This document contains side effect information about ceftaroline. Some dosage forms listed on this page may not apply to the brand name Teflaro.

Applies to ceftaroline: intravenous powder for solution.

Serious side effects of Teflaro

Along with its needed effects, ceftaroline (the active ingredient contained in Teflaro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ceftaroline:

More common

Less common

Incidence not known

Other side effects of Teflaro

Some side effects of ceftaroline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to ceftaroline: intravenous powder for injection.


The most common side effects reported in adults using this drug were diarrhea, headache, nausea, pruritus, and rash.[Ref]


Very common (10% or more): Direct antiglobulin test/Coombs test seroconversion (up to 32.3%), positive direct Coombs test

Uncommon (0.1% to 1%): Anemia, leukopenia, neutropenia, thrombocytopenia, prolonged prothrombin time, prolonged activated partial thromboplastin time, increased INR

Rare (0.01% to 0.1%): Agranulocytosis, eosinophilia[Ref]

In clinical trials, direct antiglobulin test seroconversion was reported in 10.7% of adult patients using this drug every 12 hours (600 mg infused over 1 hour every 12 hours) and in 32.3% of those using this drug every 8 hours (600 mg infused over 2 hours every 8 hours). Seroconversion from negative to positive direct Coombs test result was reported in 17.9% of children using this drug.

Agranulocytosis, eosinophilia, and leukopenia have also been reported during postmarketing experience.[Ref]


Common (1% to 10%): Diarrhea, nausea, constipation, vomiting, abdominal pain

Uncommon (0.1% to 1%): Clostridioides difficile colitis

Frequency not reported: C difficile-associated diarrhea, dyspepsia[Ref]


Common (1% to 10%): Rash, pruritus, generalized pruritus

Uncommon (0.1% to 1%): Urticaria

Beta-lactam antibiotics (including cephalosporins):

-Postmarketing reports: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms [DRESS], acute generalized exanthematous pustulosis)[Ref]

In clinical trials using this drug every 12 hours or every 8 hours, rash was common; however, in a subgroup of Asian patients using this drug every 8 hours, rash was very common (18.5%).[Ref]

Nervous system

Risk of encephalopathy was higher in patients with renal dysfunction receiving doses of this drug that were not appropriately reduced.[Ref]

Common (1% to 10%): Headache, dizziness

Frequency not reported: Convulsion

Postmarketing reports: Encephalopathy[Ref]


Common (1% to 10%): Hypokalemia

Frequency not reported: Decreased appetite, hyperglycemia, hyperkalemia[Ref]


Common (1% to 10%): Phlebitis, hypertension, increased blood pressure

Frequency not reported: Bradycardia, palpitations[Ref]


Common (1% to 10%): Increased transaminases, increased ALT

Frequency not reported: Abnormal hepatic function, hepatitis, increased AST[Ref]


Common (1% to 10%): Pyrexia

Frequency not reported: Asthenia[Ref]


Common (1% to 10%): Insomnia[Ref]


Common (1% to 10%): Infusion site reactions (erythema, phlebitis, pain)


Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterials.[Ref]

Uncommon (0.1% to 1%): Hypersensitivity (e.g., urticaria, lip and face swelling), anaphylaxis[Ref]


Uncommon (0.1% to 1%): Increased blood creatinine

Frequency not reported: Renal failure[Ref]


Postmarketing reports: Eosinophilic pneumonia


Frequency not reported: Urinary tract infection[Ref]


1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Teflaro (ceftaroline). Forest Pharmaceuticals. 2010.

4. Ceftaroline fosamil (Teflaro) - a new IV cephalosporin. Med Lett Drugs Ther. 2011;53:5-6.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.